The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 28, 2015

Filed:

May. 05, 2010
Applicants:

Ashim K. Mitra, Overland Park, KS (US);

Poonam R. Velagaleti, Randolph, NJ (US);

Ulrich M. Grau, New York, NY (US);

Inventors:

Ashim K. Mitra, Overland Park, KS (US);

Poonam R. Velagaleti, Randolph, NJ (US);

Ulrich M. Grau, New York, NY (US);

Assignee:

Aurinia Pharmaceuticals Inc., Victoria, BC, CA;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/14 (2006.01); A61K 31/56 (2006.01); A61K 31/573 (2006.01); A61K 9/00 (2006.01); A61K 9/107 (2006.01); A61K 31/14 (2006.01); A61K 31/436 (2006.01); A61K 47/10 (2006.01); A61K 47/22 (2006.01);
U.S. Cl.
CPC ...
A61K 31/573 (2013.01); A61K 9/0048 (2013.01); A61K 9/107 (2013.01); A61K 31/14 (2013.01); A61K 31/436 (2013.01); A61K 47/10 (2013.01); A61K 47/22 (2013.01); Y10S 514/912 (2013.01);
Abstract

Topical drug delivery systems for ophthalmic use including mixed nanomicellar formulations of water-insoluble drugs and methods of treating diseases affecting the posterior ocular segments are disclosed. In an embodiment, an aqueous ophthalmic solution includes nanomicelles in a physiologically acceptable buffer, having a pH of 5.0 to 8.0, wherein a corticosteroid at a concentration from about 0.01% w/v to about 1.00% w/v is solubilized through entrapment in a mixed micellar hydrophobic core with a corona composed of hydrophilic chains extending from the hydrophobic core, wherein the nanomicelles comprise vitamin E TPGS at a concentration ranging from about 3.0% w/v to about 5.0% w/v stabilized with octoxynol-40 at a concentration ranging from about 1.0% w/v to about 3.0% w/v.


Find Patent Forward Citations

Loading…